251 related articles for article (PubMed ID: 19199782)
1. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y
J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782
[TBL] [Abstract][Full Text] [Related]
2. Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan.
Srivastava SK; Shefali S; Miller CN; Aceto MD; Traynor JR; Lewis JW; Husbands SM
J Med Chem; 2004 Dec; 47(26):6645-8. PubMed ID: 15588100
[TBL] [Abstract][Full Text] [Related]
3. Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.
Zaidi SA; Arnatt CK; He H; Selley DE; Mosier PD; Kellogg GE; Zhang Y
Bioorg Med Chem; 2013 Nov; 21(21):6405-13. PubMed ID: 24055076
[TBL] [Abstract][Full Text] [Related]
4. Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.
Yuan Y; Li G; He H; Stevens DL; Kozak P; Scoggins KL; Mitra P; Gerk PM; Selley DE; Dewey WL; Zhang Y
ACS Chem Neurosci; 2011 Jul; 2(7):346-51. PubMed ID: 22816021
[TBL] [Abstract][Full Text] [Related]
5. 6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.
Williams DA; Zheng Y; David BG; Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Selley DE; Dewey WL; Akbarali HI; Zhang Y
ACS Chem Neurosci; 2016 Aug; 7(8):1120-9. PubMed ID: 27269866
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2007 May; 50(9):2254-8. PubMed ID: 17407276
[TBL] [Abstract][Full Text] [Related]
8. Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.
Zheng Y; Obeng S; Wang H; Stevens DL; Komla E; Selley DE; Dewey WL; Akbarali HI; Zhang Y
ACS Chem Neurosci; 2018 Dec; 9(12):3028-3037. PubMed ID: 30001114
[TBL] [Abstract][Full Text] [Related]
9. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.
Yuan Y; Zaidi SA; Elbegdorj O; Aschenbach LC; Li G; Stevens DL; Scoggins KL; Dewey WL; Selley DE; Zhang Y
J Med Chem; 2013 Nov; 56(22):9156-69. PubMed ID: 24144240
[TBL] [Abstract][Full Text] [Related]
11. Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.
Zhang Y; Braithwaite A; Yuan Y; Streicher JM; Bilsky EJ
Eur J Pharmacol; 2014 Aug; 736():124-30. PubMed ID: 24815322
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.
Neumeyer JL; Zhang B; Zhang T; Sromek AW; Knapp BI; Cohen DJ; Bidlack JM
J Med Chem; 2012 Apr; 55(8):3878-90. PubMed ID: 22439881
[TBL] [Abstract][Full Text] [Related]
13. Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.
Obeng S; Jali A; Zheng Y; Wang H; Schwienteck KL; Chen C; Stevens DL; Akbarali HI; Dewey WL; Banks ML; Liu-Chen LY; Selley DE; Zhang Y
ACS Chem Neurosci; 2019 May; 10(5):2518-2532. PubMed ID: 30758946
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2006 Jan; 49(1):256-62. PubMed ID: 16392810
[TBL] [Abstract][Full Text] [Related]
15. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.
Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Mosier PD; Kellogg GE; Dewey WL; Selley DE; Zhang Y
Bioorg Med Chem; 2015 Apr; 23(8):1701-15. PubMed ID: 25783191
[TBL] [Abstract][Full Text] [Related]
16. High-affinity carbamate analogues of morphinan at opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1508-11. PubMed ID: 17276685
[TBL] [Abstract][Full Text] [Related]
17. Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.
Ananthan S; Khare NK; Saini SK; Davis P; Dersch CM; Porreca F; Rothman RB
Bioorg Med Chem; 2003 Sep; 11(18):4143-54. PubMed ID: 12927876
[TBL] [Abstract][Full Text] [Related]
18. Major effect of pyrrolic N-benzylation in norbinaltorphimine, the selective kappa-opioid receptor antagonist.
Chauvignac C; Miller CN; Srivastava SK; Lewis JW; Husbands SM; Traynor JR
J Med Chem; 2005 Mar; 48(5):1676-9. PubMed ID: 15743210
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.
Yuan Y; Elbegdorj O; Chen J; Akubathini SK; Zhang F; Stevens DL; Beletskaya IO; Scoggins KL; Zhang Z; Gerk PM; Selley DE; Akbarali HI; Dewey WL; Zhang Y
J Med Chem; 2012 Nov; 55(22):10118-29. PubMed ID: 23116124
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.
Vekariya RH; Lei W; Ray A; Saini SK; Zhang S; Molnar G; Barlow D; Karlage KL; Bilsky EJ; Houseknecht KL; Largent-Milnes TM; Streicher JM; Ananthan S
J Med Chem; 2020 Jul; 63(14):7663-7694. PubMed ID: 32530286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
